methyl 3-((4-methoxyphenyl)sulfonamido)thiophene-2-carboxylate | 206192-42-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-((4-methoxyphenyl)sulfonamido)thiophene-2-carboxylate
• 英文别名: methyl 3-[(4-methoxyphenyl)sulfonylamino]thiophene-2-carboxylate
• CAS: 206192-42-9
• 化学式: C₁₃H₁₃NO₅S₂
• mdl: MFCD01243949
• 分子量: 327.382
• InChiKey: CFFRKUKUGKQGFU-UHFFFAOYSA-N

物化性质

• 沸点：
  493.3±55.0 °C(Predicted)
• 密度：
  1.423±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 3-((4-methoxyphenyl)sulfonamido)thiophene-2-carboxylate 在 水 、 potassium carbonate 、 caesium carbonate 、 sodium hydroxide 、 palladium dichloride 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.13h， 生成 4-(4-methoxyphenylsulfonyl)-4,5-dihydrothieno[3,2-c]isoquinoline
  参考文献：
  名称：

  Design, structure-activity relationship study and biological evaluation of the thieno[3,2-c]isoquinoline scaffold as a potential anti-cancer agent

  摘要：

  DOI：

  10.1016/j.bmcl.2021.128327
• 作为产物：
  描述：

  3-氨基-2-噻吩甲酸甲酯 、 对甲氧基苯磺酰氯 在 吡啶 作用下， 以 氯仿 为溶剂， 以6.89 g (66%)的产率得到methyl 3-((4-methoxyphenyl)sulfonamido)thiophene-2-carboxylate
  参考文献：
  名称：

  Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors

  摘要：

  该式化合物在治疗由TNF-α介导的疾病条件中具有用处，如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退行性损失。

  公开号：

  US06200996B1

文献信息

• [EN] THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR<br/>[FR] MODULATEURS DE RÉCEPTEUR CCR9 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ENCYSIVE PHARMACEUTICALS INC

  公开号：WO2009044311A1

  公开（公告）日：2009-04-09

  Provided are compounds of Formula (I) or of Formula (II) that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or amelioratin diseases associated with modulation of CCR9 receptor activity.

  提供了符合Formula (I)或Formula (II)的化合物，这些化合物是CCR9受体活性调节剂，含有这些化合物的组合物以及这些化合物和组合物的使用方法。在某些实施例中，提供了用于治疗或改善与调节CCR9受体活性相关的疾病的方法。
• Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
  申请人：American Cyanamid Company

  公开号：US06200996B1

  公开（公告）日：2001-03-13

  Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr; such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  该式化合物在治疗由TNF-α介导的疾病条件中具有用处，如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退行性损失。
• Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as
  申请人：American Cyanamid Company

  公开号：US05962481A1

  公开（公告）日：1999-10-05

  The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization. The TACE and MMP inhibiting ortho-sulfonamido aryl hydroxamic acids of the present invention are represented by the formula ##STR1## where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A where A is defined as: a 5-6 membered heteroaryl having from 1 to 3 heteroatoms independently selected from N, O, and S and optionally substituted by R.sup.1, R.sup.2 and R.sup.3 ; and Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are described in the specification, and the pharmaceutically acceptable salts thereof and the optical isomers and diastereomers thereof.

  本发明涉及新型、低分子量、非肽类基质金属蛋白酶抑制剂（例如明胶酶、基质金属蛋白酶和胶原酶）以及TNF-α转化酶（TACE，肿瘤坏死因子-α转化酶）的发现，这些抑制剂对于治疗这些酶涉及的疾病非常有用，例如关节炎、肿瘤生长和转移、血管生成、组织溃疡、异常伤口愈合、牙周病、骨病、蛋白尿、动脉瘤性主动脉疾病、创伤性关节损伤后的退行性软骨丢失、神经系统的脱髓鞘疾病、移植排斥、消瘦、厌食、炎症、发热、胰岛素抵抗、脓毒性休克、充血性心力衰竭、中枢神经系统的炎症性疾病、炎症性肠病、艾滋病毒感染、年龄相关性黄斑变性、糖尿病视网膜病变、增殖性玻璃体视网膜病变、早产儿视网膜病变、眼部炎症、角膜圆锥、Sjogren综合征、近视、眼部肿瘤、眼部血管生成/新生。 本发明的TACE和MMP抑制的ortho-磺酰胺基芳基羟肟酸由以下公式表示：##STR1##其中，羟肟酸基团和磺酰胺基团与A组上相邻的碳键合，其中A被定义为：具有1至3个异构原子（独立选择自N、O和S）的5-6成员杂环，可选地被R1、R2和R3取代；Z、R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中描述，以及其药学上可接受的盐和其光学异构体和对映异构体。
• [EN] THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] THIÉNOISOQUINOLÉINES ET LEURS DÉRIVÉS POUR LE TRAITEMENT DU CANCER
  申请人：VALORBEC SEC

  公开号：WO2018102920A1

  公开（公告）日：2018-06-14

  The present disclosure relates to fused N-arylsulfonamidyl-thienoisoquinoline compounds, derivatives and pharmaceutical compositions thereof, and methods and uses in inhibiting cancer cell growth, along with a supplemental anti-cancer agent. Centrosome targeting and microtubule depolymerisation are attractive in designing the present chemotherapeutic compounds. The various diseases and conditions treated include various types of cell cancers, and in vitro inhibition.

  本公开涉及融合的N-芳基磺胺基噻吩异喹啉化合物，其衍生物和药物组合物，以及在抑制癌细胞生长方面的方法和用途，以及辅助抗癌药物。针对中心粒和微管去聚合是设计目前化疗化合物的吸引点。治疗的各种疾病和病况包括各种类型的细胞癌和体外抑制。
• [EN] THIENOISOQUINOLINES AND THEIR DERIVATIVES FOR TARGETING TUBULIN, CH-TOG, AURORA A KINASE, TPX2, CDK5RAP2 AND/OR ASPM<br/>[FR] THIÉNOISOQUINOLINES ET LEURS DÉRIVÉS POUR LE CIBLAGE DE TUBULINE, CH-TOG, AURORA A KINASE, TPX2, CDK5RAP2 ET/OU ASPM
  申请人：VALORBEC SEC

  公开号：WO2019095066A1

  公开（公告）日：2019-05-23

  The present disclosure relates to compounds, methods and uses thereof for targeting tubulin, ch-TOG, Aurora A kinase, TPX2, Cdk5rap2 and/or ASPM and for the treatment of cancer in a subject. For example, the compounds can comprise compounds of Formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof. A, Z, RA, RB, R1, R2, R3, R4 and R5 can have different values.

  本公开涉及化合物、方法和用途，用于针对微管蛋白、ch-TOG、Aurora A激酶、TPX2、Cdk5rap2和/或ASPM以及治疗受试者的癌症。例如，这些化合物可以包括式I的化合物或其药用可接受的盐、溶剂或前药。A、Z、RA、RB、R1、R2、R3、R4和R5可以具有不同的值。